Considering Equity and Consumer Impacts of GLP-1 Drugs – A UBS Economist Weighs In
Since the introduction of GLP-1 drugs on the market, their use has split into two categories: for obesity and “recreationally,” according to the Chief Economist with UBS (formerly known as Union Bank of Switzerland). Paul Donovan, said economist, discusses The economics of getting thin in his regularly published comment blog. “These different uses have different economic consequences,” Donovan explains: Obese patients who use GLP-1s should become more productive employees, Donovan expects — less subject to prejudice, and less likely to be absent from work. While so-called recreational GLP-1 consumers may experience these
I'm in amazing company here with other #digitalhealth innovators, thinkers and doers. Thank you to Cristian Cortez Fernandez and Zallud for this recognition; I'm grateful.
Jane was named as a member of the AHIP 2024 Advisory Board, joining some valued colleagues to prepare for the challenges and opportunities facing health plans, systems, and other industry stakeholders. Looking forward to AHIP 2024 in Las Vegas come June 11-13, 2024.
Join Jane at AHIP's annual meeting in Las Vegas: I'll be speaking, moderating a panel, and providing thought leadership on health consumers and bolstering equity, empowerment, and self-care.